Microchip's Recovery Accelerates: Strong Demand and Pricing Power Shift Thesis

What happened

Microchip Technology is emerging from its worst downturn, with Q1 FY2027 sales up 38% YoY and bookings indicating demand now outstrips supply. Management's mid-year price increases have been well-received, lead times are stretching, and data center sales are expected to grow ~69% to ~$1B in CY2026. While the company remains cyclical with capped gross margins and $5.1B in net debt, forward valuation metrics (20.72x FWD P/E, 0.46x FWD PEG) appear attractive relative to growth. This follows a period of stabilization noted in the prior DeepValue report, where bookings had turned positive and distributor inventory days were falling. The key watch items from that report—sustained book-to-bill above 1.05, improved pricing, and leverage reduction—appear to be materializing.

Implication

Longer-term, Microchip's recovery appears to be gaining momentum, with data center exposure providing a new growth vector. However, the company's high net debt and historical cyclicality warrant continued monitoring of balance sheet metrics (net debt/EBITDA and interest coverage) and cost-saving execution. If management achieves its long-term margin targets and deleverages, the stock could re-rate; otherwise, risk remains. We would look for sustained bookings strength and margin expansion before committing sizeable capital. The forward P/E of 20.72x assumes significant earnings recovery, so any demand hiccup could compress the multiple.

Thesis delta

The thesis shifts from WAIT to a more positive stance as demand recovery and pricing power confirm the cyclical upturn. The prior concerns around trough earnings and high leverage are alleviating, with forward earnings positive and data center growth adding upside. However, balance sheet deleveraging must be confirmed, and margin expansion remains key to sustaining the re-rating.